IAG Partners with BMC/BUSM
London, UK and Boston, MA - Image Analysis Group (IAG) announced today that they have partnered with a new CRO spun out by BMC/BUSM Radiology to provide life sciences, biotech, medical device and pharmaceutical clients with expert clinical research services in imaging.
This partnership will offer IAG’s proprietary cloud-based platform Dynamika for clinical trial data management, patented advanced image analysis algorithms for imaging data analysis, and renowned scientific and analytical expertise of the radiologists to conduct global clinical trials.
The partnership will allow for BMC/BUSM Radiology to market IAG’s industry leading cloud based software platform for clinical trial data management and image analysis DYNAMIKA while IAG’s’ clients will benefit from BMC/BUSM radiology and clinical services expertise in oncology, immune-oncology, neuro-oncology, neurology and inflammation. The new partners will work in tandem to provide trial and endpoint design, trial management, site selection and management, project management, technical expert and radiology services globally.
“We believe that the combination of the technology platform, algorithms and services and with BMC Radiology’s medical depth creates a clinical trial imaging management team unrivalled in the industry”, commended Dr. Olga Kubassova, CEO of Image Analysis Group.
“We are pleased to gain a partner with such complementary skills and look forward to working together,” added the president of Boston Radiology Associates, Dr. Jorge Soto.
About Image Analysis Group
Image Analysis Group is an expert clinical research organization, delivering systems, scientific expertise and full service to support efficient design and execution of clinical trials, where imaging provides critical evidence of the novel compound safety and efficacy.
About BMC/BUSM Radiology
Boston Medical Center Radiology is a group of academic radiologists with research expertise and extensive clinical trials experience in all specialties including oncology, neuro-oncology, trauma etc. Members of the department have recognized proficiency in clinical trials design, execution and management.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
